/

ARVN

Arvinas, Inc.Closed

6.84−0.61 −8.19%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 6.74 −1.46%

Open

7.43

Prev close

7.45

Day range

6.807.50

52-week range

6.8014.51

Volume

852.86K1.08×

Mkt cap

441.33M

P/E ttm

26.31

Fwd P/E

-2.12

EPS ttm

0.2600

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−52.86%

Price Chart

Yahoo Finance · delayed

ARVNOct 13, 2026O 7.54H 7.54L 6.80C 6.84−0.61 (−8.19%)Vol 852.90K

SMA 508.51
SMA 2009.98

1Y change −27.70% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ARVN Arvinas, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.43%
1 month: −19.05%
3 months: −17.29%
6 months: −37.82%
Year to date: −42.33%
1 year: −30.20%

Valuation & ownership

Market cap: 441.33M
Enterprise value: −112.66M
P/E (ttm): 26.31
Forward P/E: -2.12
PEG ratio: —
Price / book: 0.79
Price / sales (ttm): 1.39
EV / EBITDA: 11.38
EPS (ttm): 0.2600
EPS (forward): -3.23
Beta (5y monthly): 1.81
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 64.52M
Float: 56.81M
Short % of float: 9.61%
Short ratio (days): 6.31
Held by insiders: 7.80%
Held by institutions: 83.96%
Avg volume (3m): 790.00K
50-day average: 8.53
200-day average: 10.01
52-week change: −30.20%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 28.7
vs 50-day SMA: −19.59%
vs 200-day SMA: −31.46%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.12%
Realised vol (20d, ann.): 50.0%
From 52-week high: −52.86%
From 52-week low: +0.59%

ANR

Analyst Consensus

14 analysts

Consensus

Buy

2.38 on a 1 (strong buy) – 5 (sell) scale

Mean target

13.93

+103.63% implied

Low 6.00Median 13.00High 21.00

Recommendation trend

Now7 / 8 / 1
1m ago / 8 /

DES

About Arvinas, Inc.

Yahoo Finance profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Sector: Healthcare
Industry: Biotechnology
Employees: 246
Headquarters: New Haven, CT, United States
Website: arvinas.com
Officers

SEAS

Seasonality · ARVN

2018–2026 · monthly returns

Strongest month Dec +34.90%Weakest month Mar −18.77%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	12.8	-0.8	-20.1	-6.6	-9.3	-7.5	-3.4	14.6	-15.9	-11.6			−42.3%
2025	-8.1	0.5	-60.3	37.0	-25.2	2.2	1.1	3.9	10.2	19.0	24.2	-5.8	−38.1%
2024	0.8	10.8	-10.2	-23.0	4.3	-19.7	3.3	-4.9	-5.8	7.3	1.1	-28.3	−53.4%
2023	-4.2	-6.5	-10.9	-4.1	-16.7	13.7	-0.4	14.1	-30.4	-17.9	36.3	87.3	+20.3%
2022	-13.0	-9.3	3.8	-18.3	-24.2	1.0	26.2	-20.3	5.1	11.7	-17.4	-16.6	−58.4%
2021	-11.2	3.8	-15.6	4.3	5.5	5.9	31.3	-14.7	-4.7	5.4	-12.7	8.6	−3.3%
2020	17.9	-2.7	-14.5	30.3	-36.6	0.8	-6.1	-17.6	-9.0	-11.4	15.7	251.0	+106.7%
2019	35.5	11.2	-23.8	41.4	0.2	5.1	21.3	-2.5	-17.1	-4.1	85.9	7.0	+219.8%
2018										-3.6	4.0	-24.0	−23.8%

INSD

Insider Activity · ARVN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

93.2K shares

Sells, 6 months

54K shares

Net shares

+39.2K

Net change in insider shares

+0.80%

Date	Insider	Transaction	Shares	Value
Jun 23, 2026	Saik AndrewChief Financial Officer	Sale at price 8.16 per share.	5.7K	$46.47K
Jun 23, 2026	Norwalk Leslie VDirector	Stock Award(Grant) at price 0.00 per share.	15.5K	—
Jun 23, 2026	Cunningham Everett VDirector	Stock Award(Grant) at price 0.00 per share.	15.5K	—
Jun 23, 2026	Bain Linda CDirector	Stock Award(Grant) at price 0.00 per share.	15.5K	—
Jun 23, 2026	Smaldone Alsup LaurieDirector	Stock Award(Grant) at price 0.00 per share.	15.5K	—
Jun 23, 2026	Morrison Briggs W. M.D.Director	Stock Award(Grant) at price 0.00 per share.	15.5K	—
Jun 23, 2026	Kennedy Edward Moore Jr.Director	Stock Award(Grant) at price 0.00 per share.	15.5K	—
Jun 16, 2026	Cacace Angela MOfficer	Sale at price 7.60 per share.	2.6K	$19.57K
May 20, 2026	Teel RandyChief Executive Officer	Sale at price 9.04 per share.	2.2K	$19.96K
May 10, 2026	Loomis David KOfficer	Sale at price 9.94 per share.	1.9K	$19.07K
May 10, 2026	Teel RandyChief Executive Officer	Sale at price 9.94 per share.	9.7K	$95.97K
May 10, 2026	Cacace Angela MOfficer	Sale at price 9.94 per share.	9.7K	$95.97K
May 10, 2026	Berkowitz NoahOfficer	Sale at price 9.94 per share.	11.1K	$110.39K
May 10, 2026	Saik AndrewChief Financial Officer	Sale at price 9.94 per share.	11.1K	$110.69K
Mar 17, 2026	Berkowitz NoahOfficer	Sale at price 11.10 per share.	6.4K	$71.43K
Mar 5, 2026	Morrison Briggs W. M.D.Director	Purchase at price 13.40 per share.	20K	$268.07K
Feb 26, 2026	Houston John GDirector	Sale at price 13.14 - 13.24 per share.	35.3K	$466.15K
Feb 25, 2026	Berkowitz NoahOfficer	Stock Award(Grant) at price 0.00 per share.	45K	—
Feb 25, 2026	Saik AndrewChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	45K	—
Feb 25, 2026	Loomis David KOfficer	Stock Award(Grant) at price 0.00 per share.	12.4K	—

13F

Investors Holding ARVN

latest 13F filings of 29 followed managers

Investors holding ARVN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.8M	0.00%	215.34K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ARVN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ARVN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arvinas, Inc.

Seasonality · ARVN

Insider Activity · ARVN

Congress Trades · ARVN

Investors Holding ARVN

Investors Holding ARVN

Congress Trades · ARVN

Insider Activity · ARVN

Seasonality · ARVN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arvinas, Inc.

Financial Snapshot

Earnings & Dividends

News